Advertisement


Julien Edeline, MD, on Biliary Tract Cancer: Results of the PRODIGY 12-ACCORD 18 Trial

2017 Gastrointestinal Cancers Symposium

Advertisement

Julien Edeline, MD, of the Centre Eugène Marquis, discusses study findings on gemcitabine and oxaliplatin vs surveillance following surgery for localized biliary tract cancer (Abstract 225).



Related Videos

Pancreatic Cancer

Sarah E. Hoffe, MD, on Pancreatic Cancer and SBRT: Pros and Cons

Sarah E. Hoffe, MD, of the Moffitt Cancer Center, discusses the controversial role of radiation in the treatment of pancreatic cancer, recent advances in delivering short courses of high-dose stereotactic body radiation therapy, and how best to integrate this new modality in borderline and locally advanced disease.

Colorectal Cancer

Cynthia L. Sears, MD, on Colon Cancer: Keynote Lecture

Cynthia L. Sears, MD, of Johns Hopkins University School of Medicine, summarizes her keynote talk on microbes, microbiota, and colon cancer. Next-generation sequencing combined with biologic studies suggests that most colorectal cancer cases have specific microbiome associations.

Colorectal Cancer

Cornelis van de Velde, MD, PhD, on Rectal Cancer: A Database Update

Cornelis van de Velde, MD, PhD, of Leiden University Medical Center, discusses the International Watch & Wait database, established to track evidence on organ-preserving strategies in patients with rectal cancer (Abstract 521).

For More Information: www.IWWD.org

Pancreatic Cancer
Hepatobiliary Cancer

Eileen M. O’Reilly, MD, on Pancreatic and Hepatobiliary Cancers: Selecting High-Impact Targets

Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, discusses a range of topics, including tyrosine kinase inhibitors, immune therapies, targeted approaches, and DNA damage repair strategies.

Gastroesophageal Cancer

Karyn A. Goodman, MD, on Esophageal Cancer: Results of CALGB 80803

Karyn A. Goodman, MD, of the University of Colorado School of Medicine, discusses initial study findings on PET scan–directed combined-modality therapy for esophageal cancer (Abstract 1).

Advertisement

Advertisement




Advertisement